Live Feeds
● TRACKER Updated 13d ago · 5 sources tracked

Lilly’s dealmaking spreads the wealth among a broad set of biotech venture investors

Eli Lilly is acquiring Merida Biosciences for up to $2.875 billion to advance treatments for serious allergic and autoimmune diseases. This purchase marks the company's 13th acquisition of 2026 and expands its presence in Massachusetts, where its local headcount now exceeds 1,400 employees. The deal reflects a broader strategy of dealmaking that distributes returns across a wide array of biotech venture investors. Merida Biosciences is described as a TED startup.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (5)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Eli Lilly is acquiring Merida Biosciences for up to $2.875 billion.
  • ✓ The acquisition aims to advance treatments for serious autoimmune and allergic diseases.
  • ✓ This is the 13th acquisition Eli Lilly has made in 2026.
  • ✓ Lilly's headcount in Massachusetts has surpassed 1,400.
🛡️ Source Corroboration: 5 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Eli Lilly announced the acquisition of Merida Biosciences for up to $2.875 billion.

Live updates

  1. Eli Lilly Acquires Merida Biosciences to Target Autoimmune Diseases

    Eli Lilly is acquiring Merida Biosciences for up to $2.875 billion to advance treatments for serious allergic and autoimmune diseases. This purchase marks the company's 13th acquisition of 2026 and expands its presence in Massachusetts, where its local headcount now exceeds 1,400 employees. The deal reflects a broader strategy of dealmaking that distributes returns across a wide array of biotech venture investors. Merida Biosciences is described as a TED startup.

    Why it matters

    Lilly is aggressively expanding its portfolio through frequent acquisitions throughout 2026. This strategy focuses on high-growth biotech sectors to diversify its treatment pipeline. The company is simultaneously scaling its physical operations and workforce in the Massachusetts biotech hub.

    What is confirmed

    • Eli Lilly is acquiring Merida Biosciences for up to $2.875 billion.
    • The acquisition aims to advance treatments for serious autoimmune and allergic diseases.
    • This is the 13th acquisition Eli Lilly has made in 2026.
    • Lilly's headcount in Massachusetts has surpassed 1,400.

    Still unconfirmed

    • The deal is valued at $2.9 billion.
    • Lilly's dealmaking is spreading wealth among a broad set of biotech venture investors.
    • Merida Biosciences is a TED startup.

    What to watch next

    • Regulatory approval timelines for the Merida Biosciences acquisition
    • Further expansion of Lilly's Massachusetts workforce
    • Additional 2026 acquisition announcements from Eli Lilly
    Sources used for this update (6)
    1. WSJ — Eli Lilly to Buy Merida Biosciences for Up to $2.875 Billion
    2. bizjournals.com — Lilly snags another Massachusetts biotech as local headcount surges past 1,400
    3. Barron's — Lilly (LLY): Pharma Giant Keeps Growing With $2.9 Billion Deal
    4. Endpoints News — Lilly’s dealmaking spreads the wealth among a broad set of biotech venture investors
    5. Endpoints News — Lilly to buy TED startup Merida Biosciences in its 13th acquisition of 2026
    6. Eli Lilly — Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community